Caffeine

Active ingredient: Caffeine Citrate

In short: Caffeine citrate is indicated for the treatment of apnea of prematurity.

LabelSagent Pharmaceuticals
Label updatedAug 10, 2026

What is Caffeine used for?

Caffeine citrate is indicated for the treatment of apnea of prematurity.

âš  Boxed warning (FDA's strongest warning)

During the double-blind, placebo-controlled clinical trial, 6 cases of necrotizing enterocolitis developed among the 85 infants studied (caffeine=46, placebo=39), with 3 cases resulting in death. Five of the six patients with necrotizing enterocolitis were randomized to or had been exposed to caffeine citrate.

Reports in the published literature have raised a question regarding the possible association between the use of methylxanthines and development of necrotizing enterocolitis, although a causal relationship between methylxanthine use and necrotizing enterocolitis has not been established. In a published randomized, placebo-controlled, clinical trial that studied the use of caffeine citrate in apnea of prematurity in approximately 2,000 patients, necrotizing enterocolitis was not more common in caffeine treated patients compared to placebo. As with all preterm infants, patients being treated with caffeine citrate should be carefully monitored for the development of necrotizing enterocolitis.

Caffeine dosage

Prior to initiation of caffeine citrate, baseline serum levels of caffeine should be measured in infants previously treated with theophylline, since preterm infants metabolize theophylline to caffeine. Likewise, baseline serum levels of caffeine should be measured in infants born to mothers who consumed caffeine prior to delivery, since caffeine readily crosses the placenta.

The recommended loading dose and maintenance doses of caffeine citrate follow.

*Using a syringe infusion pump

**Beginning 24 hours after the loading dose

Dose of Caffeine Citrate Volume | Dose of Caffeine Citrate mg/kg | Route | Frequency

Loading Dose | 1 mL/kg | 20 mg/kg | Intravenous*(over 30 minutes) | One Time

Maintenance Dose | 0.25 mL/kg | 5 mg/kg | Intravenous*(over 10 minutes) or Orally | Every 24 hours**

NOTE THAT THE DOSE OF CAFFEINE BASE IS ONE-HALF THE DOSE WHEN EXPRESSED AS CAFFEINE CITRATE (e.g., 20 mg of caffeine citrate is equivalent to 10 mg of caffeine base).

Serum concentrations of caffeine may need to be monitored periodically throughout treatment to avoid toxicity. Serious toxicity has been associated with serum levels greater than 50 mg/L.

Caffeine citrate should be inspected visually for particulate matter and discoloration prior to administration. Vials containing discolored solution or visible particulate matter should be discarded.

To test for drug compatibility with common intravenous solutions or medications, 20 mL of caffeine citrate injection were combined with 20 mL of a solution or medication. The physical appearance of the combined solutions was evaluated for precipitation. The admixtures were mixed for 10 minutes and then assayed for caffeine. The admixtures were then continually mixed for 24 hours, with further sampling for caffeine assays at 2, 4, 8, and 24 hours.

Based on this testing, caffeine citrate injection, 60 mg per 3 mL is chemically stable for 24 hours at room temperature when combined with the following test products.

Dextrose Injection, USP 5%

50% Dextrose Injection USP

Warnings & precautions

Do not take this medicine if: Caffeine citrate is contraindicated in patients who have demonstrated hypersensitivity to any of its components.

Apnea of prematurity is a diagnosis of exclusion. Other causes of apnea (e.g., central nervous system disorders, primary lung disease, anemia, sepsis, metabolic disturbances, cardiovascular abnormalities, or obstructive apnea) should be ruled out or properly treated prior to initiation of caffeine citrate.

Caffeine is a central nervous system stimulant and in cases of caffeine overdose, seizures have been reported. Caffeine citrate should be used with caution in infants with seizure disorders.

The duration of treatment of apnea of prematurity in the placebo-controlled trial was limited to 10 to 12 days. The efficacy of caffeine citrate for longer periods of treatment has not been established. Safety and efficacy of caffeine citrate for use in the prophylactic treatment of sudden infant death syndrome (SIDS) or prior to extubation in mechanically ventilated infants have also not been established.

Although no cases of cardiac toxicity were reported in the placebo-controlled trial, caffeine has been shown to increase heart rate, left ventricular output, and stroke volume in published studies. Therefore, caffeine citrate should be used with caution in infants with cardiovascular disease.

Caffeine citrate should be administered with caution in infants with impaired renal or hepatic function. Serum concentrations of caffeine should be monitored and dose administration of caffeine citrate should be adjusted to avoid toxicity in this population. .

Parents/caregivers of patients receiving caffeine citrate oral solution should receive the following instructions:

Caffeine citrate does not contain any preservatives and each vial is for single-dose only. Any unused portion of the medication should be discarded. …

Caffeine side effects

Overall, the reported number of adverse events in the double-blind period of the controlled trial was similar for the caffeine citrate and placebo groups. The following table shows adverse events that occurred in the double-blind period of the controlled trial and that were more frequent in caffeine citrate-treated patients than placebo.

Adverse Event (AE) | Caffeine Citrate

N=46 | Placebo

N=39

n (%) | n (%)

BODY AS A WHOLE

Accidental Injury | 1 (2.2) | 0 (0.0)

Feeding Intolerance | 4 (8.7) | 2 (5.1)

Sepsis | 2 (4.3) | 0 (0.0)

CARDIOVASCULAR SYSTEM

Hemorrhage | 1 (2.2) | 0 (0.0)

DIGESTIVE SYSTEM

Necrotizing Enterocolitis | 2 (4.3) | 1 (2.6)

Gastritis | 1 (2.2) | 0 (0.0)

Gastrointestinal Hemorrhage | 1 (2.2) | 0 (0.0)

HEMIC AND LYMPHATIC SYSTEM

Disseminated Intravascular Coagulation | 1 (2.2) | 0 (0.0)

METABOLIC AND NUTRITIVE DISORDERS

Acidosis | 1 (2.2) | 0 (0.0)

Healing Abnormal | 1 (2.2) | 0 (0.0)

NERVOUS SYSTEM

Cerebral Hemorrhage | 1 (2.2) | 0 (0.0)

RESPIRATORY SYSTEM

Dyspnea | 1 (2.2) | 0 (0.0)

Lung Edema | 1 (2.2) | 0 (0.0)

SKIN AND APPENDAGES

Dry Skin | 1 (2.2) | 0 (0.0)

Rash | 4 (8.7) | 3 (7.7)

Skin Breakdown | 1 (2.2) | 0 (0.0)

SPECIAL SENSES

Retinopathy of Prematurity | 1 (2.2) | 0 (0.0)

UROGENITAL SYSTEM

Kidney Failure | 1 (2.2) | 0 (0.0)

In addition to the cases above, three cases of necrotizing enterocolitis were diagnosed in patients receiving caffeine citrate during the open-label phase of the study. …

About this medicine

Both Caffeine Citrate Injection, USP for intravenous administration and Caffeine Citrate Oral Solution, USP are clear, colorless, sterile, non-pyrogenic, preservative-free, aqueous solutions adjusted to pH 4.7. Each mL contains 20 mg caffeine citrate (equivalent to 10 mg of caffeine base) prepared in solution by the addition of 10 mg caffeine anhydrous to 5 mg citric acid monohydrate, 8.3 mg sodium citrate dihydrate and Water for Injection, USP.

Caffeine, a central nervous system stimulant, is an odorless white crystalline powder or granule, with a bitter taste. It is sparingly soluble in water and ethanol at room temperature. The chemical name of caffeine is 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione. In the presence of citric acid it forms caffeine citrate salt in solution. The structural formula and molecular weight of caffeine citrate follows.

Caffeine citrate

C14H18N4O9 | MW 386.31

How it works: Caffeine is structurally related to other methylxanthines, theophylline, and theobromine. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5f38c395-0093-4afd-89ec-f96e5dc0934a. Read the full official label on DailyMed.